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Dendritic cells (DC) produce interleukin-12 (IL-12) in response to Toll-like receptor (TLR) 
activation. Two major TLR signaling pathways participate in the response to pathogens: the 
nuclear factor-
 
 
 
B (NF-
 
 
 
B)–dependent pathway leading to inflammatory cytokine secretion 
including IL-12 and the interferon (IFN)-dependent pathway inducing type I IFN and IFN-
regulated genes. Here we show that the two pathways cooperate and are likely both 
necessary for inducing an optimal response to pathogens. R-848/Resiquimod (TLR7 ligand in 
the mouse and TLR7/8 ligand in human) synergized with poly(I:C) (TLR3 ligand) or 
lipopolysaccharide (LPS; TLR4 ligand) in inducing high levels of bioactive IL-12p70 secretion 
and IFN-
 
 
 
 mRNA accumulation by mouse bone marrow–derived DC (BM-DC). Strikingly, 
IL-12p70 but not IL-12p40 secretion was strongly reduced in BM-DC from STAT1
 
 
 
/
 
 
 
 and 
IFNAR
 
 
 
/
 
 
 
 mice. STAT1 tyrosine-phosphorylation, IL-12p35, and IFN-
 
 
 
 mRNA accumulation 
were strongly inhibited in IFNAR
 
 
 
/
 
 
 
 BM-DC activated with the TLR ligand combinations. 
Similar observation were obtained in human TLR8-expressing monocyte-derived DC (moDC) 
using neutralizing anti-IFNAR2 antibodies, although results also pointed to a possible 
involvement of IFN-
 
 
 
1 (also known as IL-29). This suggests that TLR engagement on DC 
induces endogenous IFNs that further synergize with the NF-
 
 
 
B pathway for optimal 
IL-12p70 secretion. Moreover, analysis of interferon regulatory factors (IRF) regulation in 
moDC suggests a role for IRF7/8 in mediating IRF3-independent type I IFN and possibly 
IL-12p35 synthesis in response to TLR7/8.
 
DCs are BM-derived APCs that play an im-
portant role in bridging innate resistance and
adaptive immunity (1). Immature DCs reside
in peripheral tissues where during infection
they release soluble mediators (cytokines, che-
mokines, and interferons) participating in the
innate inflammatory responses. After capture
of pathogen-derived antigens and activation by
pathogens, DCs migrate from tissues via the
lymph to lymphoid organs where they become
mature DCs and prime naive T cells to initiate
acquired immune responses.
DCs recognize motifs that are conserved be-
tween large classes of microbial pathogens and
bind to germline-encoded receptors (2). Among
these receptors, the family of Toll-like receptors
(TLR) is composed of at least 11 members that
are differentially expressed among inflammatory
cells (3, 4). TLR are type 1 transmembrane pro-
teins characterized by the presence of an extra-
cellular domain containing leucine-rich repeats
(LRR) involved in ligand recognition and a
cytoplasmic Toll/IL-1 receptor (TIR) domain
similar to that of the IL-1R family and involved
in activation of signal transduction (5, 6). Each
member of the TLR family recognizes molecu-
lar structures of the different classes of pathogens
and triggers a specific cellular activation pro-
gram through the recruitment of cytoplasmic
adaptors to their TIR domain (5–7). Two major
independent but complementary pathways in
TLR signaling are classically considered: (a) the
nuclear factor-
 
 
 
B (NF-
 
 
 
B) activation through
recruitment of the adaptor MyD88 upon TLR2,
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4, 7, 8, and 9 activation or TIR-containing adaptor inducing
IFN-
 
 
 
 (TRIF)–TIR-containing adaptor molecule (TICAM)-1
upon TLR3 activation, leading to the production of inflam-
matory cytokines such as IL-1
 
 
 
, IL-6, TNF-
 
 
 
, and IL-12, and
(b) the IFN regulatory factor 3 (IRF3) activation through
TRIF–TICAM-1 recruitment to TLR3 and TLR4 leading to
type I IFN production and subsequently to induction of IFN-
responsive genes such as antiviral genes and the CXC–chemo-
kine IP-10/CXCL10 (6, 8). Additionally, recent observations
have identified IRF7 as an important effector in TLR7-, 8-,
and 9-mediated type I IFN production (9, 10).
Several populations of DCs have been characterized. My-
eloid DCs have been described both in humans and in the
mouse and produce IL-12 upon TLR engagement (3, 11,
12). They express TLR2, TLR3, and TLR4, in both species,
whereas TLR7 is only expressed in the mouse myeloid DCs
and TLR8 in the human ones. The plasmacytoid DC (pDC),
alternatively named natural type I IFN producer, have also
been identified in both species and are the main producers of
type I IFN in response to viruses, although in mouse they can
also produce IL-12 (13, 14). TLR7 and TLR9 are the main
receptors expressed on pDCs involved in virus and bacteria
recognition and type I IFN production through a strictly
MyD88-dependent signaling pathway (15).
IL-12, a cytokine that augments the cytolytic activity and
induces IFN-
 
 
 
 production and proliferation in NK and T
cells, is a potent inducer of Th1 responses and is considered
as a bridge between innate resistance and adaptive immunity
(12, 16–18). The bioactive form of IL-12 is the het-
erodimeric IL-12p70 composed of the p35 and the p40
chains encoded by separate genes. Free IL-12p40 is often
produced in large excess over the IL-12p70 heterodimer.
The initial production of IL-12 occurs rapidly and is inde-
pendent of IFN-
 
 
 
 and of signals from T cells (19, 20), how-
ever, production of IL-12p70 is facilitated by stimulation
through CD40-ligand (21) and IFN-
 
 
 
 priming (22). The in
vitro models for myeloid DCs classically used to study secre-
tion of IL-12p70 are BM-derived DCs (BM-DCs) in mouse
and monocyte-derived DCs (moDCs) in human. In the
mouse system, IFN-
 
 
 
 priming is usually required in order to
observe significant IL-12p70 secretion in response to TLR
stimulation (22, 23). In contrast, human moDCs produce
IL-12p70 in response to single TLR stimulation (12).
Although large amount of type I IFN, mainly IFN-
 
 
 
, are
produced by pDCs after exposure to viruses (14, 24), most cells
including myeloid DCs can produce IFN-
 
 
 
 (25, 26). Because
IFN-
 
 
 
 is a potent enhancer of IL-12p70 secretion and because
IFN-
 
 
 
 and type I IFN receptors activate a common signaling
pathway through STAT1 phosphorylation (25, 27), we investi-
gated whether endogenous type I IFN play a role in IL-12p70
production. Herein, using BM-DCs from type I IFN receptor
deficient (IFNAR
 
 
 
/
 
 
 
) or STAT1
 
 
 
/
 
 
 
 mice or human moDCs
cultured in the presence of anti-IFNAR blocking antibodies,
we demonstrated that IL-12p70 production in response to
TLR activation was dependent on production of endogenous
type I IFN that regulated IL-12p35 mRNA accumulation.
 
RESULTS
R-848 synergizes with LPS or poly(I:C) in inducing IL-12p70 
secretion by mouse BM-DCs
 
We analyzed whether combinations of ligands for different
TLR could induce IL-12p70 secretion by mouse BM-DCs
in the absence of exogenous IFN. As previously reported,
high levels of IL-12p40 were induced after activation with
LPS or R-848 (28) and less efficiently with poly(I:C) (Fig. 1
A). In contrast, when used alone, these ligands induced only
very low levels of IL-12p70 (Fig. 1 B). However, the com-
bination of R-848 with LPS- or poly(I:C)-induced secretion
of IL-12p70 at levels comparable to that induced by LPS in
the presence of exogenous IFN-
 
 
 
 (Fig. 1 B). Moreover,
neutralization of IL-10 by anti–IL-10R antibody increased
the production of IL-12p70 by BM-DCs activated by com-
binations of R-848 with either LPS or poly(I:C) (Fig. 1 B).
Production of IL-12p40 was also increased by these combi-
nations and further up-regulated by neutralizing IL-10 (Fig.
1 A). No synergy for IL-12p70 production was observed
Figure 1. R-848 synergizes with LPS or poly(I:C) in inducing 
IL-12p70 secretion by mouse BM-DCs without IFN-  priming. 
BM-DCs from wild-type mice (129Sv) were activated with LPS (25 ng/ml), 
R-848 (10  M), or poly(I:C) (25  g/ml) alone or in combination, or with 
LPS plus IFN-  (20 ng/ml) in the presence of 10  g/ml anti-IL10 receptor 
mAb (anti–IL-10R) or rat IgG1 control mAb. After 24 h, supernatants were 
collected and (A) IL-12p40 and (B) IL-12p70 were measured using specific 
ELISA. Data are expressed as mean   SD of culture triplicates and are rep-
resentative of four experiments. 
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with PGN plus R-848, PGN plus LPS (unpublished data) or
LPS plus poly(I:C) combinations with or without anti–
IL-10R antibody (Fig. 1). To favor IL-12 secretion, all fur-
ther experiments with mouse BM-DCs were performed in
the presence of anti–IL-10R antibodies.
 
STAT1 is required for optimal IL-12p70 production
 
STAT1 is an essential component of the signaling cascade of
both type I and type II IFN receptors (25). Because IFN
 
 
 
 in-
creased IL-12 through STAT1 phosphorylation and because
we also observed in BM-DCs STAT1 phosphorylation in re-
sponse to TLR activation (see Fig. 4), we analyzed the capac-
ity of BM-DCs derived from STAT1
 
 
 
/
 
 
 
 mice to produce IL-
12 in response to TLR ligand combinations. No differences in
phenotype were observed by flow cytometry analysis of BM-
DCs from wild-type or STAT1
 
 
 
/
 
 
 
 mice (Fig. 2 A) and they
produced similar amounts of IL-6 upon activation (Fig. 2 B).
Unlike IL-6, secretion of the IFN-dependent CXCL10 che-
mokine (29) was almost completely abrogated in BM-DCs
from STAT1
 
 
 
/
 
 
 
 mice (Fig. 2 C). Interestingly, IL-12p70
secretion was dramatically decreased in BM-DCs from
STAT1
 
 
 
/
 
 
 
 mice activated with combinations of R-848 with
LPS or poly(I:C) (Fig. 2 D), whereas production of IL-12p40
(Fig. 2 E) was either not affected for the TLR alone or only
weakly decreased for the selected ligand combinations. These
results indicated that IL-12p70, but not IL-12p40 secretion
was strongly dependent on a STAT1-dependent pathway.
Figure 2. STAT1 is required for optimal IL-12p70 production by 
BM-DCs. (A) Similar phenotype of BM-DCs derived from wild-type (WT), 
STAT1 / , and IFNAR /  mice. Expression of CD8 , CD11b, CD11c, and 
CD86 was analyzed by flow cytometry on BM-DCs derived from the indi-
cated mice. (B–E) BM-DCs from wild-type or STAT1 /  mice were acti-
vated for 24 h with different TLR ligands and their combinations in the 
presence of anti–IL-10R mAb as described in Fig. 1. Concentrations of (B) 
IL-6 , (C) CXCL10, (D) IL-12p70, and (E) IL-12p40 were quantified in super-
natants by specific ELISA. Data are expressed as mean   SD of culture 
triplicates and are representative of three experiments. Statistical signifi-
cance is indicated (**P   0.01).
Figure 3. Type I IFNs are required for optimal IL-12p70 production 
by mouse BM-DCs. (A and C) BM-DCs from wild-type (wt) or IFNAR /  
mice were activated with the TLR ligands indicated and their combinations 
in the presence of anti–IL-10R mAb as described in Fig. 1. (B) BM-DCs 
from wild-type, STAT1 / , or IFNAR /  mice were activated with the com-
bination R-848 plus LPS and with or without 20 ng/ml IFN- . Superna-
tants were collected after 24 h and (A and B) IL-12p70 and (C) IL-12p40 
were measured using specific ELISA. Data are expressed as mean   SD of 
culture triplicates and are representative of three experiments. Statistical 
significance comparing results from each deficient mice to wild-type mice 
is indicated (*P   0.05; **P   0.01). 
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Type I IFN are required for optimal IL-12p70 secretion
 
To determine whether the role of STAT1 in IL-12p70 se-
cretion was linked to endogenous IFN production, we per-
formed similar experiments using IFN-
 
  
 
 receptor 1–defi-
cient mice (IFNAR
 
 
 
/
 
 
 
). As shown in Fig. 3 A, a strong
reduction (
 
 
 
75% decrease) of IL-12p70 production induced
by the selected TLR ligand combinations was observed with
BM-DCs from IFNAR
 
 
 
/
 
 
 
 mice. As expected, BM-DCs
from IFNAR
 
 
 
/
 
 
 
, but not from STAT1
 
 
 
/
 
 
 
 mice, could re-
spond to exogenous IFN-
 
 
 
 as evidenced by augmentation of
the IL-12p70 production in response to R-848 and LPS
(Fig. 3 B). Unlike IL-12p70, IL-12p40 secretion was only
slightly affected by the absence of functional type I IFN re-
ceptor (Fig. 3 C). Moreover, no significant inhibition of
IL-6 but strong inhibition of CXCL10 production was ob-
served with IFNAR
 
 
 
/
 
 
 
 BM-DCs (unpublished data). These
data showed that BM-DCs from IFNAR
 
 
 
/
 
 
 
 mice behaved
essentially as cells derived from STAT1
 
 
 
/
 
 
 
 mice. Indeed,
R-848, poly(I:C), LPS and their combinations induced tyro-
sine-phosphorylation of STAT1 in BM-DCs from wild-type
mice but not in BM-DCs derived from IFNAR
 
 
 
/
 
 
 
 mice
(Fig. 4). Altogether this suggested that endogenous type I
IFNs were involved in the observed IL-12p70 secretion in
response to the combination of R-848 with either LPS or
poly(I:C).
 
Accumulation of IL-12p35 and type I IFN mRNA is strongly 
reduced in BM-DCs from IFNAR
 
 
 
/
 
 
 
 mice
 
Real-time PCR for IL-12p35 and IL-12p40 mRNA were
performed with BM-DCs from wild-type and IFNAR
 
 
 
/
 
 
Figure 4. Tyrosine phosphorylation of STAT1 by TLR ligands and 
their combinations requires a type I IFN pathway. BM-DCs from wild-
type or IFNAR1 /  mice were activated with IFN-  (1,000 U/ml), IFN-  
(20 ng/ml), or different TLR ligands at concentration described in Fig. 1. 
After 2 h, stimulation was stopped with cold PBS and BM-DCs were resus-
pended in lysis buffer. After SDS-PAGE and Western blot, membranes were 
incubated with anti-phosphotyrosine STAT1 (pY-STAT1) or anti-STAT1 
antibodies and analyzed as described in Materials and methods. Results are 
representative of three experiments.
Figure 5. Induction of IL-12p35, IL-12p40, IFN- , and IFN-  
mRNA in TLR-stimulated wild-type and IFNAR1 /  BM-DCs. BM-DCs 
from wild-type or IFNAR1 /  mice were activated with TLR ligands indi-
cated in the presence of anti-IL10R antibodies as described in Fig. 1. After 
4.5 h, stimulations were stopped with cold PBS and mRNA was extracted 
and reverse transcribed. Real-time PCR was performed using primers spe-
cific for mouse (A) IL-12p35, (B) IL-12p40 , (C) IFN- , or (D) IFN-  (all genes) 
genes on cDNA normalized with GAPDH. Data are expressed as -fold in-
duction of the gene of interest over GAPDH calculated with the following 
formula (1.8[CT GAPDH   CT gene]). Percentages of inhibition are indicated. 
Statistical significance is indicated (*P   0.05; **P   0.01). Results are 
representative of three experiments. 
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mice. As shown in Fig. 5 (A and B), IL-12 p35 and p40
mRNA were induced in BM-DCs from wild-type mice af-
ter a 4.5-h activation by LPS or R-848 and at higher levels
by the combination of R-848 with either LPS or poly(I:C).
The induction of IL-12p35 mRNA accumulation was
strongly decreased in BM-DCs from IFNAR /  mice (50–
80% decrease; Fig. 5 A), although that of IL-12p40 was de-
creased to a lower degree (20–40% decrease; Fig. 5 B). Thus,
TLR-induced IL-12p35 mRNA accumulation was more
dependent on type I IFN than that of IL-12p40 mRNA,
consistent with the stronger decrease of IL-12p70 than IL-
12p40 secretion by blocking type I IFN signaling.
Real-time PCR for type I IFN showed marginal induc-
tion of IFN–  mRNA by treatment with LPS and R-848
and strong up-regulation by poly(I:C) and the combinations
of R-848 plus either LPS or poly(I:C) (Fig. 5 C). However,
IFN-  mRNA accumulation was strongly reduced in
IFNAR /  BM-DCs in all conditions (Fig. 5 C). In con-
trast, using primers hybridizing to all IFN-  genes, very low
IFN-  mRNA accumulation was detected only in response
to poly(I:C) and R-848 plus poly(I:C) combination in wild-
type BM-DCs, but again not in IFNAR /  BM-DCs (Fig.
5 D). This strong inhibition of IFN- /  induction was most
likely a consequence of the absence of an IFN-dependent
amplification loop for type I IFN in BM-DCs from
IFNAR / mice (30).
IL-12 secretion, STAT1 phosphorylation, and IRF1 induction 
in human moDCs in response to TLR ligands
Like mouse BM-DCs, human moDCs secreted very high
levels of IL-12 when activated with R-848 and LPS (31) or
poly(I:C) combinations (Fig. 6, A and B). However, as
moDCs produced relatively high levels of IL-12p70 upon
single TLR ligand stimulation (12; Fig. 6 A), all further anal-
ysis were performed using single TLR activation. LPS and
R-848 but not poly(I:C) also promoted strong secretion of
IL-12p40 (Fig. 6 B). Activation with PGN (Fig. 6, A and B)
or other TLR2 ligands like PAM3Cys and zymosan (unpub-
lished data) did not promote IL-12p70 secretion while in-
ducing IL-12p40. Tyrosine phosphorylation of STAT1 was
observed upon LPS, R-848, and poly(I:C) activation, with
R-848 inducing a rapid STAT1 phosphorylation already de-
tectable after a 1-h stimulation (Fig. 6 C). Interestingly,
PGN was the only TLR activator that did not induce ty-
rosine phosphorylation of STAT1 and IL-12p70 secretion.
In contrast, induction of IRF1, an IFN-inducible transcrip-
tion factor (32), was observed whatever TLR ligand used in-
cluding PGN (Fig. 6 D). Inhibition of protein synthesis with
cycloheximide (CHX) almost completely inhibited STAT1
tyrosine phosphorylation in response to R-848 and poly(I:C)
and partially that induced in response to LPS (Fig. 6 D). As
expected, the presence of CHX, did not affect the STAT1
tyrosine phosphorylation directly induced by a mixture of
IFN-  and IFN-  (Fig. 6 D), but inhibited the synthesis of
IRF1 protein in response to IFN- /  and the different TLR
ligands (Fig. 6 D).
Type I IFN participate in IL-12p70 secretion by human 
moDCs in response to R-848 and LPS
Addition of a neutralizing anti–human IFNAR2 antibody
partially blocked IL-12p70 secretion by moDCs in response
to LPS and R-848 (Fig. 7 A). The levels of IL-12p70 in-
duced by poly(I:C) were generally too low to conclude on a
significant effect of anti-IFNAR2 mAb (unpublished data).
No effect of anti-IFNAR2 mAb was observed on IL-12p40
production after LPS or R-848 activation (Fig. 7 B). Addi-
tion of exogenous type II or type I IFN (IFN-  or - ) dur-
ing LPS or R-848 activation up-regulated IL-12p70 secre-
tion by moDCs (Fig. 7 C) but did not modify IL-12p40
production (unpublished data). Secretion of CXCL10 in re-
Figure 6. TLR-induced IL-12p70 secretion by human moDCs is 
correlated with the capacity of the TLR ligand to induce STAT1 
tyrosine phosphorylation. (A and B) moDCs were activated for 24 h with 
or without optimal concentrations of LPS, R-848, poly(I:C), PGN, or their 
combinations. (A) IL-12p70 and (B) IL-12p40 were measured in superna-
tants using specific ELISA. Data are expressed as mean   SD of six experi-
ments performed with different donors. (C) moDCs were cultured with or 
without 30 ng/ml IFN- , LPS, PGN, poly(I:C), R-848, or DMSO (1/1,000 final 
dilution for R-848 control). (D) moDCs were activated with or without the 
TLR ligands as in C for 1 or 4 h (C) or 2 h (D), or a mixture of IFN-  and 
IFN-  (500 U/ml each) in presence or not of CHX (25  g/ml) added 15 min 
before activation. Activations were stopped with cold PBS, moDCs were 
resuspended in lysis buffer. After SDS-PAGE and Western blot, membranes 
were incubated with anti-pY-STAT1, anti-STAT1, or anti-IRF1 antibodies 
and analyzed as described in Materials and methods. Results are represen-
tative of three independent experiments.ENDOGENOUS TYPE I IFN AND TLR-INDUCED IL-12P70 SECRETION BY DCS | Gautier et al. 1440
sponse to LPS or R-848 was only partially inhibited by the
anti-IFNAR2 antibody (Fig. 7 D). Furthermore, this anti-
body also only partially inhibited LPS- and R-848–induced
STAT1 phosphorylation in moDCs, whereas it totally neu-
tralized that induced by 1,000 U/ml of IFN-  (Fig. 7 E) or
IFN-  (unpublished data). This suggests that this antibody
either could not achieved complete neutralization of the
type I IFN receptor in TLR ligand-activated moDCs or that
other mechanisms were implicated in both STAT1 tyrosine
phosphorylation and induction of IFN-dependent molecules
such as CXCL10 in human moDCs.
Analysis of type I IFN expression by real-time PCR in-
dicated that IFN-  mRNA was induced in moDCs after
LPS and R-848 activation (Fig. 8). In contrast, IFN- 
mRNA (all genes) was only very weakly induced by LPS or
R-848 (Fig. 8). Confirming real-time PCR, IFN-  produc-
tion was not detected at the protein level in supernatants of
activated-moDCs, although IFN-  could be readily de-
tected in response to LPS (unpublished data). Interestingly,
IFN- 1 (IL-29) mRNA was found to be induced by LPS
and R-848 in moDCs (Fig. 8), indicating that IFN other
than type I IFNs, that does not use the type I IFN receptor 1
and receptor 2 chains but signals through STAT1 activation
(27, 33, 34) might be involved in STAT1 phosphorylation
and possibly in IL-12p70 secretion in moDCs.
Unlike LPS and poly(I:C), R-848 did not activate IRF3 in 
moDCs, but induced IRF7 and IRF8
To address whether LPS and R-848 used a common signaling
pathway for inducing IFN in moDCs, we analyzed the activa-
tion status of IRF3 that has been described as the major tran-
scription factor involved in IFN-  induction after its phos-
phorylation and translocation within the nucleus (35, 36).
However, unlike LPS and poly(I:C), R-848 did not induce
nuclear translocation of IRF3 in moDCs (unpublished data).
Furthermore, serine-phosphorylated IRF3 was detected only
in nuclear extracts of moDCs activated by LPS or poly(I:C)
but not in cells stimulated with R-848 (Fig. 9 A). Thus, these
data suggest that R-848 may induce type I IFN in moDCs
through an IRF3-independent pathway. The expression of
other IRFs involved in type I IFN gene regulation (30) was
then analyzed by real-time PCR. In accordance with a previ-
ous study (37), we detected a weak constitutive expression of
IRF4, IRF5, and IRF7 mRNA in resting moDCs. However,
IRF7, but not IRF4 and IRF5, mRNA was found to accumu-
late in moDCs activated with LPS, poly(I:C) or R-848 (Fig. 9
B). Finally, IRF8 expression was also increased after LPS and
R-848 but not poly(I:C) activation in moDCs (Fig. 9 B).
Figure 7. Neutralizing type I IFN partially blocks LPS- and R-848–
induced IL-12p70 secretion and STAT1 tyrosine phosphorylation in 
human moDCs. (A, B, and D) moDCs were activated for 24 h with or with-
out LPS or R-848 in the presence or the absence of 30  g/ml neutralizing 
anti-IFNAR2 antibodies (CD118) or IgG2a control mAb. Concentrations of 
(A) IL-12p70, (B) IL-12p40, and (D) CXCL10 were quantified by specific 
ELISA in supernatants. Statistical significance of results with anti-IFNAR2 
mAb compared with control mAb is indicated (*P   0.05; ** P   0.01). 
(C) moDCs were activated with LPS or R-848 with or without exogenous 
IFN- , IFN- , or IFN-  and IL-12p70 was quantified by ELISA after a 24-h 
incubation. Data are expressed as mean   SD of culture triplicates and are 
representative of three experiments with different donors. Statistical sig-
nificance is indicated (*P   0.05; **P   0.01). (E) moDCs were pretreated 
for 30 min with or without 30  g/ml neutralizing anti-IFNAR2 antibodies 
or IgG2a control mAb and then activated for 2 h with or without LPS, 
R-848, or 1,000 U/ml IFN- . Analysis of pY-STAT1 in moDCs lysates was 
performed by Western blot analysis as described in Fig. 6. Results are 
representative of three independent experiments.
Figure 8. Induction of IFN- , IFN- , and IFN- 1 (also know as IL-29) 
mRNA in TLR-stimulated human moDCs. moDCs were activated for 4 h 
with or without LPS or R-848. mRNA were extracted and reverse transcribed. 
Real-time PCR was performed using primers specific for human IFN- , IFN-  
all genes, or IFN- 1 (also known as IL-29) with cDNA normalized to GAPDH 
expression. Expression of the gene of interest was quantified by applying the 
formula 1.8(CT GAPDH   CT gene of interest). Data are expressed as the -fold induction 
of the gene of interest in the different activation conditions compared 
with medium and are representative of four independent experiments.JEM VOL. 201, May 2, 2005 1441
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DISCUSSION
In the present study we demonstrate that an autocrine loop
of type I IFN is required for bioactive IL-12p70 secretion by
myeloid DCs. This conclusion is supported by the following
observations: (a) both in humans and mice, all TLR ligands
tested or their combinations that lead to IL-12p70 produc-
tion also induced STAT1 tyrosine phosphorylation; (b)
TLR2 ligands that did not trigger STAT1 phosphorylation
failed to stimulate IL-12p70 secretion; (c) optimal IL-12p70
production correlated with the strongest type I IFN induc-
tion; (d) BM-DCs from STAT1 /  mice did not produce
IL-12p70; (e) BM-DCs from IFNAR /  mice did not phos-
phorylate STAT1 and secreted neither IL-12p70 nor synthe-
sized IL-12p35 mRNA; and (f) in human moDCs, STAT1
phosphorylation and IL-12p70 production were altered by
neutralizing anti-IFNAR2 antibodies whereas IL-12p70 se-
cretion was amplified by addition of exogenous type I IFN.
Induction of type I IFN has been demonstrated to play
an important role in the cascade of gene expression after
TLR signaling (26, 38, 39). In particular, TLR3, 4, 7, and 9,
but not TLR2 activation can induce synthesis and secretion
of IFN-  by monocytes–macrophages and DCs that second-
arily acts through an autocrine–paracrine loop to induce the
expression of IFN-regulated genes (29, 40–42). In agree-
ment with previous studies on TLR3 and TLR4 (42–44),
we show that STAT1 tyrosine phosphorylation observed in
BM-DCs in response to R-848 and to R-848/LPS or
R-848/poly(I:C) combinations is dependent on type I IFN
receptor signaling.
The requirement for type I IFN in IL-12p70 production
reported herein was not previously described mainly because
most investigations in mice used IFN-  priming for IL-12
production thus masking the requirement for endogenous
type I IFN. Moreover, most previous studies with macro-
phages or DCs from IFNAR /  or STAT1 /  mice have
only analyzed the expression of the p40 gene that is less de-
pendent on endogenous IFN synthesis and signaling (45,
46). Our observation is consistent with previous studies in
humans showing that exogenous type I IFN enhances IL-
12p70 production (47, 48). Other studies in mice and hu-
mans reported that type I IFN blocks IL-12 production but
most studies have analyzed IL-12p40 or used nonspecific
bioassays for IL-12 p70 (49–54), and applied type I IFN con-
centration far higher compared with the low levels endoge-
nously detected in our systems. Thus, this discrepancy is
likely to be related in part to differential effects of high versus
low dose or long lasting versus short exposure to type I IFN
as previously reported (55, 56). Nevertheless, these observa-
tions show that upon in vivo viral infection IL-12 can be
produced in the absence of type I IFN possibly as a conse-
quence of contribution of other types of IFN (IFN- , IFN- ).
In this context, and in agreement with a recent report (57),
we observed that LPS- and R-848–activated moDCs can
produce IFN- 1 that may contribute to STAT1 phosphory-
lation (33, 34) and IL-12p70 production.
The role of STAT1 phosphorylation in IL-12p70 pro-
duction may shed new light on the in vivo deficiency ob-
served in STAT1 /  mice or in STAT1-deficient human
patients (58, 59). In particular, an abrogated type I IFN loop
may also result in an impaired IL-12p70 production partici-
pating in the deficiency in TH-1 immune responses ob-
served in these deficiencies.
IL-12 is an inflammatory cytokine whose production is
dependent on NF- B activation (12) and our study shows
that the TLR signaling pathway leading to type I IFN pro-
duction cooperates with the NF- B–dependent pathway to
trigger bioactive IL-12p70 production. Accordingly, TLR2
ligands that do not activate the IFN-dependent pathway
only induce IL-12p40 production in a MyD88- and NF- B-
dependent manner. Importantly our results point to a role of
type I IFN in the accumulation of IL-12p35 transcripts.
Figure 9. (A) LPS and poly(I:C) but not R-848, induce nuclear 
translocation of phosphorylated IRF3 in moDCs. moDCs were activated 
with or without the indicated TLR ligands. At the time indicated, stimula-
tions were stopped with cold PBS and nuclei were isolated as described 
in Materials and methods. After SDS-PAGE of nuclear extracts and West-
ern blot, membranes were incubated with anti-pY-STAT1 or anti-phos-
pho-IRF3 (p-IRF3) antibodies and analyzed as described in Materials and 
methods. Results are representative of three independent experiments. (B) 
Expression of IRF7, IRF8, IRF4, and IRF5 mRNA in TLR-stimulated human 
moDCs. moDCs were activated for 1 or 4 h with or without LPS, poly(I:C)
or R-848. mRNA were extracted and reverse transcribed. Real-time PCR 
was performed using primers specific for the human IRF indicated with 
cDNA normalized to GAPDH expression. Expression of the gene of 
interest was quantified by applying the formula 1.8(CT GAPDH   CT gene of interest). 
Data are expressed as the -fold induction of the gene of interest in the 
different activation conditions compared with medium and are represen-
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IRF1 and NF- B/c-Rel have been shown to play major
roles in the transcriptional activation of the IL-12p35 gene
(60, 61). We observed IRF1 induction in response to TLR
ligands suggesting that endogenous type I IFN may trigger
IRF1 production required for transcription induction of IL-
12p35. However, other signaling pathways such as TLR2
can also lead to IRF1 induction without triggering of IL-
12p70, suggesting the cooperation between several transcrip-
tion factors for IL-12p35 induction. Of interest, Liu et al.
(62) recently reported that ICSBP/IRF8 acts in synergy with
IRF1 to activate IL-12p35 mRNA transcription through
binding to an ICSBP-response element in the human IL-
12p35 promoter. The sequence of this binding element does
not match the conventional IRFE and ISRE sequences, or
the newly described subset of ISRE (ETS/IRF response ele-
ment, EIRE) that can interact with ICSBP, IRF4, and PU.1
(63). It has also been recently shown that TLR7 and prob-
ably TLR9 activation forms a complex with MyD88,
TRAF6, and IRF7 that results in IRF7 activation (9, 10).
We observed up-regulation of IRF8 and IRF7, but not of
IRF4 or IRF5 in response to LPS, R-848, or poly(I:C) acti-
vation. Thus, it is likely that induction/activation of IRF1
and IRF8 or possibly IRF7 by TLR7 and TLR8 and the
role of IFN and STAT1 in their induction may be important
for optimal IL-12p35 expression.
We show a selective synergistic activity between R-848
and either LPS or poly(I:C) for IFN /  and IL-12p70 pro-
duction in mouse BM-DCs and in human moDCs. This
synergy may be dependent on the cooperative recruitment
of MyD88 by TLR7 in the mouse and by TLR8 in human
moDCs and TRIF by TLR4 and TLR3. The absence of
synergy between LPS and poly(I:C) may be related to the
common use of TRIF and possible competition for this
adaptor. Alternatively, induction/activation of transcription
factors of the IRF family are most likely candidates to ex-
plain the synergy between TLR4 or TLR3 and TLR7/8 ac-
tivation for type I IFN and possibly IL-12 up-regulation.
IRF3 is constitutively expressed by myeloid DCs (37) and
activated through TLR3 and TLR4 engagement but not by
TLR8 in human moDCs and by TLR7 in the mouse (10).
Thus, the synergy between TLR3/4 and TLR7/8 might be
due to the IRF3-dependent synthesis of IFN-  through
TLR3/4 activation that further acts in an autocrine/para-
crine feedback loop to induce IRF7 synthesis. IRF7 can be
then activated by TLR7 or TLR8 engagement (in mouse
BM-DCs or human moDCs, respectively) to promote opti-
mal type I IFN and possibly IL-12p35 synthesis. It would be
important to validate this hypothesis to assess the status of
IRF7 phosphorylation upon TLR7/8 only versus TLR7/8
and TLR3/4 engagement.
Natural ligands for mTLR7 and hTLR8 are ssRNA rich
in uracil and guanosin found in different viruses and also
RNA from host cells (64–66). It is therefore possible that
during viral infections the release of viral RNA and/or host
RNA from endocytosed infected cells may simultaneously
engage both TLR3 and TLR7 or TLR8 within endosomal
compartments of DCs. Moreover, several reports have
shown TLR4-mediated responses to certain viruses (67–72)
and TLR4 endogenous ligands (such as HSP60) might be in-
duced during viral infection. In bacterial and parasitic infec-
tions production of type I IFN in addition to TLR-induced
proinflammatory cytokines has also been shown (73, 74).
Thus, physiological conditions engaging simultaneously
TLR7/8 and other MyD88-signaling TLR with either
TLR3/4 or other pathways of type I IFN production may
represent optimal responses to certain infections. Similarly,
during certain specific infections leading to both pDCs and
myeloid DCs activation, a paracrine loop of type I IFN from
pDCs may amplify IL-12 production from myeloid DCs.
The simultaneous and synergic activation of both pathways
in vivo is probably indicative of a serious productive infec-
tion and may be needed to signal a full-fledged innate and
adaptive response, whereas the simple presence of individual
TLR ligands may only results in a limited and transient in-
flammatory response. It was recently suggested that the syn-
ergistic stimulation of innate responses in mice by dsRNA
and CpG DNA (75) could be exploited therapeutically for
activating antitumor resistance.
MATERIALS AND METHODS
Hematopoietic factors, cytokines, reagents
Mouse cells were cultured in RPMI 1640 medium supplemented with 5%
heat-inactivated FCS, 2 mM L-glutamine (Life Technologies), 50  M  2-
mercaptoethanol (Sigma-Aldrich), and 100  g/ml gentamycin (Schering-
Plough). Recombinant TNF-  and GM-CSF (R&D Systems) were used at
a final concentration of 100 U/ml and 10 ng/ml, respectively. Rat anti–
mouse IL-10 receptor antibodies (clone 1B1.3A) were used at a concentra-
tion of 10  g/ml (DNAX).
Human cells were cultured in RPMI 1640 medium supplemented with
10% heat-inactivated FCS, 2 mM L-glutamine, and 100  g/ml gentamycin.
Hematopoietic factors and cytokines were recombinant human proteins.
GM-CSF, IL-4, IFN- 2b (Schering-Plough Research Institute), IFN- ,
and IFN-  (R&D Systems) were used at optimal concentration of 100 ng/
ml, 10 ng/ml, 1,000 U/ml, 20 ng/ml, and 1,000 U/ml, respectively.
Mouse anti–human IFNAR2 antibodies (CD118; PBL Biomedical Labora-
tories) and mouse anti–human IL-10 receptor (3c5.2b) antibodies (DNAX)
were used at the concentration of 30 and 10  g/ml, respectively.
BM-DCs or moDCs were activated with 25 ng/ml Escherichia coli LPS
(Sigma-Aldrich), 10  M R-848 (synthesized at Schering-Plough Research
Institute), 10  g/ml PGN from Staphylococcus aureus (Sigma-Aldrich), or 25
 g/ml poly(I:C; InvivoGen). All cytokines and TLR ligands, except LPS,
were shown to be endotoxin-free, as determined by a Limulus-Amebocyte
Assay (BioWhittaker).
Mice
Female 129Sv, IFNAR /  (129Sv background), and STAT1 /  (129Sv
background) mice, 6–10 wk old, were purchased from B&K Universal or
Taconic, bred at the Charles River animal facility, and maintained in our fa-
cilities under standard conditions. Procedures involving animals and their
care were conducted in conformity with European Economic Community
Council Directive 86/609, OJL 358,1, December 12, 1987.
Generation of DCs from human monocytes or from 
mice BM progenitors
Mouse BM-derived DCs. Mice were killed by CO2 inhalation. BM cells
were flushed out of the bones with cold PBS–FCS–EDTA. For cell deple-
tions, cells were incubated for 30 min at 4 C with a mixture of the mAbs:JEM VOL. 201, May 2, 2005 1443
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anti-CD3 molecular complex (17A2), anti-CD8  (53–5.8), anti-CD11b
(M1/70), anti-CD19 (1D3), anti-Ly6G/C (RB6-8C5), and antierythrocyte
(TER119; all antibodies from BD Biosciences). Cells and goat anti–rat IgG–
coated Dynabeads (Dynal) were mixed under agitation for 15 min at 4 C.
Beads and attached cells were removed with a Dynal magnet. Depleted cells
were cultured in 24-well culture plates at 2   105 cells/ml in the presence
of GM-CSF and TNF- . At day 3, 50% of the medium was removed and
fresh medium containing GM-CSF plus TNF-  was added for the next 2 d.
Flow cytometry analysis was performed on a FACScalibur flow cytometer
(BD Biosciences) with rat anti–mouse CD8  (53–6.7), anti-CD11b (M1/
70), CD86 (GL1), and hamster anti-CD11c (HL3; BD Biosciences).
Human moDCs. PBMC were purified from human peripheral blood by
Ficoll-Hypaque centrifugation. Monocytes were purified by adherence after
preparation of PBMC followed by a 52% Percoll gradient and differentiated
into moDCs after 5 d in the presence of GM-CSF and IL-4 (76).
Quantification of cytokine production
BM-DCs or moDCs were cultured at 105 cells/well in 200  l in 96-well flat-
bottom culture plates and stimulated with LPS, R-848, poly(I:C), PGN, or
combinations of ligands for 24 h. Culture supernatants were collected and IL-
12p70, IL-12p40, IL-6, and IP-10 levels were determined by specific ELISA
kits from R&D Systems for mouse and BD Biosciences for human cytokines.
Analysis of STAT1 and IRF3 phosphorylation
Cells were collected, washed once in RPMI 1% FCS, starved overnight in
RPMI 1% FCS, and activated for different times with different activators.
Stimulation was stopped by addition of cold PBS. Cells were washed and lysed
in GBL lysis buffer on ice for 30 min. Then, lysates were centrifuged and
phosphatase and protease inhibitors were added (phosphatase inhibitor cocktail
set I, protease inhibitor cocktail set III; Calbiochem-Novabiochem). 1 vol of
2  SB (Novex) containing Bond Breaker TCEP solution (Pierce Chemical
Co.) was added to lysates. In some experiments, nuclei were isolated from
moDCs using the CelLytic nuclear extraction kit (Sigma-Aldrich). Lysates
were boiled for 2 min at 95 C before running on a SDS-PAGE Tris-glycine
(4–20%) gel. Transfer was at 85 V for 90 min in transfer buffer (Novex) con-
taining 20% of methanol using PVDF membrane transfer (Immobilon-P; Mil-
lipore). Membrane was blocked with PBS 0.2% tween 20 (Sigma-Aldrich), 3%
BSA (Sigma-Aldrich) for 45 min. Membranes was incubated overnight at
4 C with antiphosphotyrosine STAT1 (Cell Signaling), anti-STAT1 (Cell
Signaling), anti-IRF1 (Santa Cruz Biotechnology) or antiphosphoserine396
IRF3 (77) antibodies at dilutions of 1/1,000, 1/1,000, 1/1,000, and 1/10,000,
respectively, in blocking buffer (PBS/BSA/Tween 20). Membranes were
washed three times in PBS/Tween20 and incubated with goat anti–rabbit sec-
ondary HRP-conjugated antibody (Jackson ImmunoResearch Laboratories) at
1/5,000 dilution. After three washes, membranes were incubated with ECL
(Amersham Biosciences) for 1 min in the dark at room temperature and devel-
oped in using Biomax MR-1 film (Eastman Kodak Co.).
RNA extraction, cDNA reverse transcriptase, and real-time 
RT-PCR analysis
Cells were lysed and total RNA was extracted by RNeasy kit (Qiagen). Ge-
nomic contamination was excluded by amplification (quantitative PCR,
Light Cycler; Bio-Rad Laboratories) of the nontranscribed part of the human
or mouse CD4 promoter (Table I; human probe: CACTGGACACAAT-
TGCCCTCAGG), mouse probe: 5 -TGGTTGAAAGATGGCTACA-
GAGAAGAGG). First-strand cDNAs were prepared as previously described
(78). Synthesis of cDNAs was controlled and normalized by performing real-
time PCR amplification of the housekeeping gene GAPDH for both human
and mouse. Real-time PCR were performed using SYBR green Master Mix
(Applied Biosystem), primers described in Table I (400 nM final) and 25 ng
of cDNA. Amplification of genes of interest and GAPDH were always per-
formed on the same plate (thermo-fast 96-wells, semi skirled; ABgene, Ep-
som) with a final volume of 25  l. Cycle conditions were one cycle for 9 min
at 94 C and then 94 C for 15 s, 60 C for 1 min for 50 cycles, followed by
one cycle at 94 C for 3 min. Expression of the gene of interest was quantified
by applying the formula 1.8(CT GAPDH CT gene of interest).
Statistical analysis
Experimental results were analyzed for statistical significance (Student’s t test
or a paired t test) using SigmaStat Software package. Statistical significance is
indicated in the figures (*P   0.05; **P   0.01).
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Table I. Primers used for PCR amplification
Forward Reverse
Human
CD4 promoter 5 -TTCCACACTGGGCCACCTAT 5 -TTGTGGGCTTACCACTGCTG
IFN-  5 -AGCTGAAGCAGTTCCAGAAG 5 -AGTCTCATTCCAGCCAGTGC
IFN-  (all genes) 5 -GTGAGGAAATACTTCCAAAGAATCAC 5 -TCTCATGATTTCTGCTCTGACAA
IFN-  1/IL-29 5 -GTGGTGCTGGTGACTTTGG 5 -CTCCTGTGGTGACAGAGATTTG
IRF4 5 -GAGCCAAGCATAAGGTCTGC 5 -TCAGCTCCTTCACGAGGATT
IRF5 5 -CGGACTGATGTGGAGATGTG 5 -CTCTCCTTCTTGGCCCAAAT
IRF7 5 -TACCATCTACCTGGGCTTCG 5 -AGGGTTCCAGCTTCACAG
IRF8 5 -GCTGATCAAGGAGCCTTCTG 5 - ACCAGTCTGGAAGGAGCTGA
Mouse
CD4 promoter 5 -GGCACTAGCTACCACCATTGTG 5 -AGGAACGATTGATGCCTTGC
IFN-  5 -GCACTGGGTGGAATGAGACT 5 -AGTGGAGAGCAGTTGAGGACA
IFN-  (all genes) 5 -TCTGATGCAGCAGGTGGG 5 -AGGGCTCTCCAGACTTCTGCTCTG
IL-12p35 5 -CACCCTTGCCCTCCTAAACC 5 -CACCTGGCAGGTCCAGAGA
IL-12p40 5 -ACAGCACCAGCTTCTTCATCAG 5 -TCTTCAAAGGCTTCATCTGCAA
GAPDH 5 -TGCACCACCAACTGCTTAG 5 -GGATGCAGGGATGATGTTCENDOGENOUS TYPE I IFN AND TLR-INDUCED IL-12P70 SECRETION BY DCS | Gautier et al. 1444
REFERENCES
1. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the con-
trol of immunity. Nature. 392:245–252.
2. Janeway, C.A., Jr., and R. Medzhitov. 2002. Innate immune recogni-
tion. Annu. Rev. Immunol. 20:197–216.
3. Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like receptors: critical
proteins linking innate and acquired immunity. Nat. Immunol. 2:675–680.
4. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annu.
Rev. Immunol. 21:335–376.
5. Dunne, A., and L.A. O’Neill. 2003. The interleukin-1 receptor/Toll-
like receptor superfamily: signal transduction during inflammation and
host defense. Sci. STKE. 2003:re3.
6. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev.
Immunol. 4:499–511.
7. Vogel, S.N., K.A. Fitzgerald, and M.J. Fenton. 2003. TLRs: differen-
tial adapter utilization by toll-like receptors mediates TLR-specific pat-
terns of gene expression. Mol. Interv. 3:466–477.
8. Weighardt, H., G. Jusek, J. Mages, R. Lang, K. Hoebe, B. Beutler, and
B. Holzmann. 2004. Identification of a TLR4- and TRIF-dependent
activation program of dendritic cells. Eur. J. Immunol. 34:558–564.
9. Kawai, T., S. Sato, K.J. Ishii, C. Coban, H. Hemmi, M. Yamamoto,
K. Terai, M. Matsuda, J. Inoue, S. Uematsu, et al. 2004. Interferon-
alpha induction through Toll-like receptors involves a direct interac-
tion of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5:1061–1068.
10. Honda, K., H. Yanai, T. Mizutani, H. Negishi, N. Shimada, N. Su-
zuki, Y. Ohba, A. Takaoka, W.C. Yeh, and T. Taniguchi. 2004. Role
of a transductional-transcriptional processor complex involving MyD88
and IRF-7 in Toll-like receptor signaling. Proc. Natl. Acad. Sci. USA.
101:15416–15421.
11. Akira, S., and H. Hemmi. 2003. Recognition of pathogen-associated
molecular patterns by TLR family. Immunol. Lett. 85:85–95.
12. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resis-
tance and adaptive immunity. Nat. Rev. Immunol. 3:133–146.
13. Cella, M., D. Jarrossay, F. Facchetti, O. Alebardi, H. Nakajima, A.
Lanzavecchia, and M. Colonna. 1999. Plasmacytoid monocytes mi-
grate to inflamed lymph nodes and produce large amounts of type I in-
terferon. Nat. Med. 5:919–923.
14. Siegal, F.P., N. Kadowaki, M. Shodell, P.A. Fitzgerald-Bocarsly, K.
Shah, S. Ho, S. Antonenko, and Y.J. Liu. 1999. The nature of the
principal type 1 interferon-producing cells in human blood. Science.
284:1835–1837.
15. Krug, A., A. Towarowski, S. Britsch, S. Rothenfusser, V. Hornung, R.
Bals, T. Giese, H. Engelmann, S. Endres, A.M. Krieg, and G. Hart-
mann. 2001. Toll-like receptor expression reveals CpG DNA as a
unique microbial stimulus for plasmacytoid dendritic cells which syner-
gizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Im-
munol. 31:3026–3037.
16. Kobayashi, M., L. Fitz, M. Ryan, R.M. Hewick, S.C. Clark, S. Chan,
R. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identifi-
cation and purification of natural killer cell stimulatory factor (NKSF),
a cytokine with multiple biologic effects on human lymphocytes. J.
Exp. Med. 170:827–845.
17. Hsieh, C.-S., S.E. Macatonia, C.S. Tripp, S.F. Wolf, A. O’Garra, and
K.M. Murphy. 1993. Development of TH1 CD4  T cells through IL-
12 produced by Listeria-induced macrophages. Science. 260:547–549.
18. Manetti, R., P. Parronchi, M.G. Giudizi, M.-P. Piccinni, E. Maggi, G.
Trinchieri, and S. Romagnani. 1993. Natural killer cell stimulatory
factor interleukin 12 (IL-12) induces T helper type 1 (Th1)-specific
immune responses and inhibits the development of IL-4-producing Th
cells. J. Exp. Med. 177:1199–1204.
19. Gazzinelli, R.T., S. Hayashi, M. Wysocka, L. Carrera, R. Kuhn, W.
Muller, F. Roberge, G. Trinchieri, and A. Sher. 1994. Role of IL-12
in the initiation of cell mediated immunity by Toxoplasma gondii and
its regulation by IL-10 and nitric oxide. J. Eukaryot. Microbiol. 41:9S.
20. Scharton-Kersten, T.M., T.A. Wynn, E.Y. Denkers, S. Bala, E. Grun-
vald, S. Hieny, R.T. Gazzinelli, and A. Sher. 1996. In the absence of
endogenous IFN-gamma, mice develop unimpaired IL-12 responses to
Toxoplasma gondii while failing to control acute infection. J. Immunol.
157:4045–4054.
21. Schulz, O., A.D. Edwards, M. Schito, J. Aliberti, S. Manickasingham,
A. Sher, and C. Reis e Sousa. 2000. CD40 triggering of heterodimeric
IL-12 p70 production by dendritic cells in vivo requires a microbial
priming signal. Immunity. 13:453–462.
22. Hayes, M.P., J. Wang, and M.A. Norcross. 1995. Regulation of inter-
leukin-12 expression in human monocytes: selective priming by inter-
feron-gamma of lipopolysaccharide-inducible p35 and p40 genes.
Blood. 86:646–650.
23. Snijders, A., P. Kalinski, C.M. Hilkens, and M.L. Kapsenberg. 1998.
High-level IL-12 production by human dendritic cells requires two
signals. Int. Immunol. 10:1593–1598.
24. Asselin-Paturel, C., A. Boonstra, M. Dalod, I. Durand, N. Yessaad, C.
Dezutter-Dambuyant, A. Vicari, A. O’Garra, C. Biron, F. Briere, and
G. Trinchieri. 2001. Mouse type I IFN-producing cells are immature
APCs with plasmacytoid morphology. Nat. Immunol. 2:1144–1150.
25. Stark, G.R., I.M. Kerr, B.R. Williams, R.H. Silverman, and R.D.
Schreiber. 1998. How cells respond to interferons. Annu. Rev. Biochem.
67:227–264.
26. Hertzog, P.J., L.A. O’Neill, and J.A. Hamilton. 2003. The interferon in
TLR signaling: more than just antiviral. Trends Immunol. 24:534–539.
27. Decker, T., S. Stockinger, M. Karaghiosoff, M. Muller, and P. Kova-
rik. 2002. IFNs and STATs in innate immunity to microorganisms. J.
Clin. Invest. 109:1271–1277.
28. Wagner, T.L., C.L. Ahonen, A.M. Couture, S.J. Gibson, R.L. Miller,
R.M. Smith, M.J. Reiter, J.P. Vasilakos, and M.A. Tomai. 1999.
Modulation of TH1 and TH2 cytokine production with the immune
response modifiers, R-848 and imiquimod. Cell. Immunol. 191:10–19.
29. Hoshino, K., T. Kaisho, T. Iwabe, O. Takeuchi, and S. Akira. 2002.
Differential involvement of IFN-beta in Toll-like receptor-stimulated
dendritic cell activation. Int. Immunol. 14:1225–1231.
30. Taniguchi, T., K. Ogasawara, A. Takaoka, and N. Tanaka. 2001. IRF
family of transcription factors as regulators of host defense. Annu. Rev.
Immunol. 19:623–655.
31. Fogel, M., J.A. Long, P.J. Thompson, and J.W. Upham. 2002. Den-
dritic cell maturation and IL-12 synthesis induced by the synthetic im-
mune-response modifier S-28463. J. Leukoc. Biol. 72:932–938.
32. Harada, H., K. Willison, J. Sakakibara, M. Miyamoto, T. Fujita, and T.
Taniguchi. 1990. Absence of the type I IFN system in EC cells: tran-
scriptional activator (IRF-1) and repressor (IRF-2) genes are develop-
mentally regulated. Cell. 63:303–312.
33. Sheppard, P., W. Kindsvogel, W. Xu, K. Henderson, S. Schlutsmeyer,
T.E. Whitmore, R. Kuestner, U. Garrigues, C. Birks, J. Roraback, et
al. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat.
Immunol. 4:63–68.
34. Kotenko, S.V., G. Gallagher, V.V. Baurin, A. Lewis-Antes, M. Shen,
N.K. Shah, J.A. Langer, F. Sheikh, H. Dickensheets, and R.P. Don-
nelly. 2003. IFN-lambdas mediate antiviral protection through a dis-
tinct class II cytokine receptor complex. Nat. Immunol. 4:69–77.
35. Hiscott, J., P. Pitha, P. Genin, H. Nguyen, C. Heylbroeck, Y. Ma-
mane, M. Algarte, and R. Lin. 1999. Triggering the interferon re-
sponse: the role of IRF-3 transcription factor. J. Interferon Cytokine Res.
19:1–13.
36. Juang, Y.T., W.C. Au, W. Lowther, J. Hiscott, and P.M. Pitha. 1999.
Lipopolysaccharide inhibits virus-mediated induction of interferon
genes by disruption of nuclear transport of interferon regulatory factors
3 and 7. J. Biol. Chem. 274:18060–18066.
37. Izaguirre, A., B.J. Barnes, S. Amrute, W.S. Yeow, N. Megjugorac, J.
Dai, D. Feng, E. Chung, P.M. Pitha, and P. Fitzgerald-Bocarsly. 2003.
Comparative analysis of IRF and IFN-alpha expression in human plas-
macytoid and monocyte-derived dendritic cells. J. Leukoc. Biol. 74:
1125–1138.
38. Akira, S., and K. Hoshino. 2003. Myeloid differentiation factor 88-
dependent and -independent pathways in toll-like receptor signaling. J.
Infect. Dis. 187:S356–S363.
39. Hoebe, K., and B. Beutler. 2004. LPS, dsRNA and the interferon
bridge to adaptive immune responses: Trif, Tram, and other TIR adap-
tor proteins. J. Endotoxin Res. 10:130–136.JEM VOL. 201, May 2, 2005 1445
ARTICLE
40. Kawai, T., O. Takeuchi, T. Fujita, J. Inoue, P.F. Muhlradt, S. Sato,
K. Hoshino, and S. Akira. 2001. Lipopolysaccharide stimulates the
MyD88-independent pathway and results in activation of IFN-regula-
tory factor 3 and the expression of a subset of lipopolysaccharide-
inducible genes. J. Immunol. 167:5887–5894.
41. Doyle, S., S. Vaidya, R. O’Connell, H. Dadgostar, P. Dempsey, T.
Wu, G. Rao, R. Sun, M. Haberland, R. Modlin, and G. Cheng. 2002.
IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immu-
nity. 17:251–263.
42. Toshchakov, V., B.W. Jones, P.Y. Perera, K. Thomas, M.J. Cody, S.
Zhang, B.R. Williams, J. Major, T.A. Hamilton, M.J. Fenton, and
S.N. Vogel. 2002. TLR4, but not TLR2, mediates IFN-beta-induced
STAT1alpha/beta-dependent gene expression in macrophages. Nat.
Immunol. 3:392–398.
43. Ohmori, Y., and T.A. Hamilton. 2001. Requirement for STAT1 in LPS-
induced gene expression in macrophages. J. Leukoc. Biol. 69:598–604.
44. Doyle, S.E., R. O’Connell, S.A. Vaidya, E.K. Chow, K. Yee, and G.
Cheng. 2003. Toll-like receptor 3 mediates a more potent antiviral re-
sponse than Toll-like receptor 4. J. Immunol. 170:3565–3571.
45. Hemmi, H., T. Kaisho, K. Takeda, and S. Akira. 2003. The roles of
Toll-like receptor 9, MyD88, and DNA-dependent protein kinase cat-
alytic subunit in the effects of two distinct CpG DNAs on dendritic
cell subsets. J. Immunol. 170:3059–3064.
46. Bradford, M., A.J. Schroeder, H.C. Morse III, S.N. Vogel, and J.S.
Cowdery. 2002. CpG DNA induced IL-12 p40 gene activation is in-
dependent of STAT1 activation or production of interferon consensus
sequence binding protein. J. Biomed. Sci. 9:688–696.
47. Heystek, H.C., B. den Drijver, M.L. Kapsenberg, R.A. van Lier, and
E.C. de Jong. 2003. Type I IFNs differentially modulate IL-12p70 pro-
duction by human dendritic cells depending on the maturation status
of the cells and counteract IFN-gamma-mediated signaling. Clin. Im-
munol. 107:170–177.
48. Hermann, P., M. Rubio, T. Nakajima, G. Delespesse, and M. Sarfati.
1998. IFN-alpha priming of human monocytes differentially regulates
gram-positive and gram-negative bacteria-induced IL-10 release and
selectively enhances IL-12p70, CD80, and MHC class I expression. J.
Immunol. 161:2011–2018.
49. Cousens, L.P., J.S. Orange, H.C. Su, and C.A. Biron. 1997. Inter-
feron-alpha/beta inhibition of interleukin 12 and interferon-gamma
production in vitro and endogenously during viral infection. Proc. Natl.
Acad. Sci. USA. 94:634–639.
50. Dalod, M., T.P. Salazar-Mather, L. Malmgaard, C. Lewis, C. Asselin-
Paturel, F. Briere, G. Trinchieri, and C.A. Biron. 2002. Interferon  / 
and interleukin 12 responses to viral infections: pathways regulating
dendritic cell cytokine expression in vivo. J. Exp. Med. 195:517–528.
51. Byrnes, A.A., X. Ma, P. Cuomo, K. Park, L. Wahl, S.F. Wolf, H.
Zhou, G. Trinchieri, and C.L. Karp. 2001. Type I interferons and IL-
12: convergence and cross-regulation among mediators of cellular im-
munity. Eur. J. Immunol. 31:2026–2034.
52. Nardelli, B., L. Zaritskaya, M. Semenuk, Y.H. Cho, D.W. LaFleur, D.
Shah, S. Ullrich, G. Girolomoni, C. Albanesi, and P.A. Moore. 2002.
Regulatory effect of IFN-kappa, a novel type I IFN, on cytokine produc-
tion by cells of the innate immune system. J. Immunol. 169:4822–4830.
53. Dalod, M., T. Hamilton, R. Salomon, T.P. Salazar-Mather, S.C.
Henry, J.D. Hamilton, and C.A. Biron. 2003. Dendritic cell responses
to early murine cytomegalovirus infection: subset functional specializa-
tion and differential regulation by interferon  / . J. Exp. Med. 197:
885–898.
54. Cousens, L.P., R. Peterson, S. Hsu, A. Dorner, J.D. Altman, R.
Ahmed, and C.A. Biron. 1999. Two roads diverged: interferon  / -
and interleukin 12-mediated pathways in promoting T cell interferon  
responses during viral infection. J. Exp. Med. 189:1315–1328.
55. Nagai, T., O. Devergne, T.F. Mueller, D.L. Perkins, J.M. van Seven-
ter, and G.A. van Seventer. 2003. Timing of IFN-beta exposure during
human dendritic cell maturation and naive Th cell stimulation has con-
trasting effects on Th1 subset generation: a role for IFN-beta-mediated
regulation of IL-12 family cytokines and IL-18 in naive Th cell differ-
entiation. J. Immunol. 171:5233–5243.
56. Biron, C.A. 2001. Interferons alpha and beta as immune regulators–a
new look. Immunity. 14:661–664.
57. Coccia, E.M., M. Severa, E. Giacomini, D. Monneron, M.E. Remoli,
I. Julkunen, M. Cella, R. Lande, and G. Uze. 2004. Viral infection and
Toll-like receptor agonists induce a differential expression of type I and
lambda interferons in human plasmacytoid and monocyte-derived den-
dritic cells. Eur. J. Immunol. 34:796–805.
58. Meraz, M.A., J.M. White, K.C. Sheehan, E.A. Bach, S.J. Rodig, A.S.
Dighe, D.H. Kaplan, J.K. Riley, A.C. Greenlund, D. Campbell, et al.
1996. Targeted disruption of the Stat1 gene in mice reveals unexpected
physiologic specificity in the JAK-STAT signaling pathway. Cell. 84:
431–442.
59. Dupuis, S., E. Jouanguy, S. Al-Hajjar, C. Fieschi, I.Z. Al-Mohsen, S.
Al-Jumaah, K. Yang, A. Chapgier, C. Eidenschenk, P. Eid, et al. 2003.
Impaired response to interferon-alpha/beta and lethal viral disease in
human STAT1 deficiency. Nat. Genet. 33:388–391.
60. Liu, J., S. Cao, L.M. Herman, and X. Ma. 2003. Differential regulation
of interleukin (IL)-12 p35 and p40 gene expression and interferon
(IFN)- -primed IL-12 production by IFN regulatory factor 1. J. Exp.
Med. 198:1265–1276.
61. Grumont, R., H. Hochrein, M. O’Keeffe, R. Gugasyan, C. White, I.
Caminschi, W. Cook, and S. Gerondakis. 2001. c-Rel regulates inter-
leukin 12 p70 expression in CD8( ) dendritic cells by specifically in-
ducing p35 gene transcription. J. Exp. Med. 194:1021–1032.
62. Liu, J., X. Guan, T. Tamura, K. Ozato, and X. Ma. 2004. Synergistic
activation of interleukin-12 p35 gene transcription by interferon regu-
latory factor-1 and interferon consensus sequence-binding protein. J.
Biol. Chem. 279:55609–55617.
63. Meraro, D., M. Gleit-Kielmanowicz, H. Hauser, and B.Z. Levi. 2002.
IFN-stimulated gene 15 is synergistically activated through interactions
between the myelocyte/lymphocyte-specific transcription factors,
PU.1, IFN regulatory factor-8/IFN consensus sequence binding pro-
tein, and IFN regulatory factor 4: characterization of a new subtype of
IFN-stimulated response element. J. Immunol. 168:6224–6231.
64. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S.
Akira, G. Lipford, H. Wagner, and S. Bauer. 2004. Species-specific
recognition of single-stranded RNA via toll-like receptor 7 and 8. Sci-
ence. 303:1526–1529.
65. Diebold, S.S., T. Kaisho, H. Hemmi, S. Akira, and C. Reis e Sousa.
2004. Innate antiviral responses by means of TLR7-mediated recogni-
tion of single-stranded RNA. Science. 303:1529–1531.
66. Lund, J.M., L. Alaxopoulou, A. Sato, M. Karow, N.C. Adams, N.W.
Gale, A. Iwasaki, and R.A. Flawell. 2004. Recognition of single-
stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci.
USA. 101:5598–5603.
67. Kurt-Jones, E.A., L. Popova, L. Kwinn, L.M. Haynes, L.P. Jones, R.A.
Tripp, E.E. Walsh, M.W. Freeman, D.T. Golenbock, L.F. Anderson,
and R.W. Finberg. 2000. Pattern recognition receptors TLR4 and
CD14 mediate response to respiratory syncytial virus. Nat. Immunol.
1:398–401.
68. Haynes, L.M., D.D. Moore, E.A. Kurt-Jones, R.W. Finberg, L.J.
Anderson, and R.A. Tripp. 2001. Involvement of toll-like receptor 4 in
innate immunity to respiratory syncytial virus. J. Virol. 75:10730–10737.
69. Rassa, J.C., J.L. Meyers, Y. Zhang, R. Kudaravalli, and S.R. Ross.
2002. Murine retroviruses activate B cells via interaction with toll-like
receptor 4. Proc. Natl. Acad. Sci. USA. 99:2281–2286.
70. Otten, L.A., D. Finke, and H. Acha-Orbea. 2002. Can MMTV exploit
TLR4? Trends Microbiol. 10:303–305.
71. Burzyn, D., J.C. Rassa, D. Kim, I. Nepomnaschy, S.R. Ross, and I.
Piazzon. 2004. Toll-like receptor 4-dependent activation of dendritic
cells by a retrovirus. J. Virol. 78:576–584.
72. Triantafilou, K., and M. Triantafilou. 2004. Coxsackievirus B4-
induced cytokine production in pancreatic cells is mediated through
toll-like receptor 4. J. Virol. 78:11313–11320.
73. Bogdan, C., J. Mattner, and U. Schleicher. 2004. The role of type I in-
terferons in non-viral infections. Immunol. Rev. 202:33–48.
74. Aksoy, E., C. Zouain, F. Vanhoutte, J. Fontaine, N. Pavelka, N. Thie-
blemont, F. Willems, P. Ricciardi-Castagnoli, M. Goldman, M. Capron,ENDOGENOUS TYPE I IFN AND TLR-INDUCED IL-12P70 SECRETION BY DCS | Gautier et al. 1446
et al. 2005. Double-stranded RNAs from the helminth parasite Schisto-
soma activate TLR3 in dendritic cells. J. Biol. Chem. 280:277–283.
75. Whitmore, M.M., M.J. DeVeer, A. Edling, R.K. Oates, B. Simons, D.
Lindner, and B.R. Williams. 2004. Synergistic activation of innate im-
munity by double-stranded RNA and CpG DNA promotes enhanced
antitumor activity. Cancer Res. 64:5850–5860.
76. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble
antigen by cultured human dendritic cells is maintained by granulocyte/
macrophage colony-stimulating factor plus interleukin 4 and downregu-
lated by tumor necrosis factor alpha. J. Exp. Med. 179:1109–1118.
77. Servant, M.J., N. Grandvaux, B.R. tenOever, D. Duguay, R. Lin, and J.
Hiscott. 2003. Identification of the minimal phosphoacceptor site re-
quired for in vivo activation of interferon regulatory factor 3 in response
to virus and double-stranded RNA. J. Biol. Chem. 278:9441–9447.
78. de Saint-Vis, B., C. Bouchet, G. Gautier, J. Valladeau, C. Caux, and P.
Garrone. 2003. Human dendritic cells express neuronal Eph receptor
tyrosine kinases: role of EphA2 in regulating adhesion to fibronectin.
Blood. 102:4431–4440.